Tianjin Pharmaceutical Group Xinzheng Co. Ltd.

Main purpose: To observe the single oral administration of the test preparation Pemafibrate tablets (specification: 0.1mg) and the reference preparation Pemafibrate tablets (trade name: PARMODIA®; specifications) to Chinese healthy subjects in the fasting/postprandial state. : 0.1 mg; license holder: Kowa Co., Ltd.) to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. . Secondary purpose: To observe the safety of the test preparation pemafibrate tablets and the reference preparation pemafibrate tablets (PARMODIA®) in Chinese healthy subjects.

Main study objectives: To investigate the pharmacokinetic characteristics of the test preparation oseltamivir phosphate capsules and the reference preparation oseltamivir phosphate capsules after a single oral administration of 75 mg on an empty stomach or after a meal in healthy adult Chinese subjects, and to preliminarily evaluate the bioequivalence of the two preparations after oral administration under fasting and after a meal conditions. Secondary study objectives: To evaluate the safety of the test preparation and the reference preparation after a single oral administration of 75 mg in healthy adult Chinese subjects.

Primary objective: To compare the differences in the extent and rate of absorption of sildenafil citrate tablets (specification: 100 mg) produced by Suicheng Pharmaceutical Co., Ltd. and sildenafil citrate tablets (trade name: Wan Ai Ke®, specification: 100 mg) produced by Pfizer Pharmaceuticals Co., Ltd. under fasting and postprandial administration in healthy people. Secondary objective: To evaluate the safety and tolerability of sildenafil citrate tablets (specification: 100 mg) produced by Suicheng Pharmaceutical Co., Ltd. and sildenafil citrate tablets (trade name: Wan Ai Ke®, specification: 100 mg) produced by Pfizer Pharmaceuticals Co., Ltd. under fasting and postprandial administration.